News
Naproxen April concessions projected to cost NHS 1.1m
In News
Stay up to date with all the news, learning and insight in the world of pharmacy.Bookmark
Record learning outcomes
The Department of Health and Social Care announced the final list of price concessions for April on April 29.
The list of 16 medicines below, published by the PSNC, came after previous announcements of 30 concession prices on April 16 and 25 prices on April 18.
Drug | Pack size | Price concession |
Bumetanide 1mg tablets | 28 | £1.39 |
Candesartan 8mg tablets | 28 | £2.30 |
Co-careldopa 25mg/100mg tablets | 100 | £10.00 |
Finasteride 5mg tablets | 28 | £1.34 |
Irbesartan 75mg tablets | 28 | £2.18 |
Irbesartan 150mg tablets | 28 | £3.16 |
Nebivolol 5mg tablets | 28 | £5.29 |
Pantoprazole 20mg tablets | 28 | £1.73 |
Pantoprazole 40mg tablets | 28 | £3.65 |
Quetiapine 200mg tablets | 60 | £12.78 |
Quetiapine 300mg tablets | 60 | £9.99 |
Riluzole 50mg tablets | 56 | £115.68 |
Risedronate sodium 35mg tablets | 4 | £7.27 |
Telmisartan 80mg tablets | 28 | £6.62 |
Tolbutamide 500mg tablets | 28 | £22.70 |
Topiramate 50mg tablets | 60 | £12.27 |
The team behind OpenPrescribing, a tool that provides a search interface onto raw prescribing data from NHS BSA, project that price concessions for generic medicines will cost the NHS an additional £7,265,7756 in April. They arrived at this figure by combining drug tariff and price concession data for April with the latest available prescribing data, which is from February 2019.
Naproxen 250mg tablets account for the largest projected overspend (projected additional cost of £713,599 in April on top of 'usual' monthly cost of £478,904), with Naproxen 500mg tablets projected to cost an additional £368,451 – bringing the total overspend on the drug to £1.08m.
The April figures point to a significant drop from the projected overspend for March – which saw a record 96 concession prices granted – according to OpenPrescribing, with concessions for that month projected to cost the NHS an additional £16,927,914 over and above payment at Drug Tariff prices.